Brief Reminders as Intervention for Greater Engagement of Cochrane Translators
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03534791 |
Recruitment Status :
Completed
First Posted : May 23, 2018
Last Update Posted : July 5, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Knowledge Translation | Other: Reminders | Not Applicable |
All study participants who accept participation in the study will be initially assigned 3 PLSs, and subsequently they will be assigned more PLSs when they translated the previous ones. Intervention group will receive one customized e-mail reminder two weeks after the PLS assignment if they do not translate it within two weeks. If they still do not translate the PLS, they will receive another customized e-mail reminder after every two weeks until they translate the PLS or until we reach maximum of 4 bi-weekly reminders (at 2 weeks, 4 weeks, 6 weeks and 8 weeks post-assignment) or until participants indicate that they are unable to translate it anymore. Text of the reminder that will be sent to the study participants is available in Supplementary file 1. The reminders will be customized for each PLS, and they will contain a name of the PLS indicated in the message. If the participants do not translate PLS within 2 months from PLS assignment, we will stop sending them reminders and we will consider them as dropouts.
Control group will receive no intervention, i.e. standard procedure. Participants in the control group will receive PLSs for translation, in the frequency they indicated, and they will not receive any reminders. They will be assigned new PLSs once they translate the ones that were previously assigned.
All PLSs will be translated in Memsource, a translation management tool that Cochrane plans to start using since March 2018 for managing translation of summaries. Participants will be followed 6 months from the moment of allocation.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 80 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | All study participants who accept participation in the study will be initially assigned 3 PLSs, and subsequently they will be assigned more PLSs when they translated the previous ones. Intervention group will receive one customized e-mail reminder two weeks after the PLS assignment if they do not translate it within two weeks. Control group will receive no intervention, i.e. standard procedure. Participants in the control group will receive PLSs for translation, in the frequency they indicated, and they will not receive any reminders. They will be assigned new PLSs once they translate the ones that were previously assigned. |
Masking: | Double (Participant, Outcomes Assessor) |
Masking Description: | Study participants will be blinded to allocation. The author who will communicate with the participants will not be blinded. Other authors and outcome assessors who will analyze data will be blinded to allocation of study participants; anonymized data will be analyzed. |
Primary Purpose: | Treatment |
Official Title: | Interventions for Increasing Volunteer Engagement in Knowledge Translation Activity of Translating Cochrane Plain Language Summaries: a Randomized Controlled Trial |
Actual Study Start Date : | May 1, 2018 |
Actual Primary Completion Date : | June 28, 2019 |
Actual Study Completion Date : | June 28, 2019 |
Arm | Intervention/treatment |
---|---|
Experimental: Reminders
Reminders customized for each PLS, containing a name of the PLS indicated in the message. If the participants do not translate PLS within 2 months from PLS assignment, we will stop sending them reminders and we will consider them as dropouts.
|
Other: Reminders
Personalized email which will aim for reminding of the translator about the PLSs on hold. |
No Intervention: Control group
Control group will receive no intervention, i.e. standard procedure. Participants in the control group will receive PLSs for translation, in the frequency they indicated, and they will not receive any reminders. They will be assigned new PLSs once they translate the ones that were previously assigned.
|
- Number of translated PLSs within the 6 month follow-up [ Time Frame: 6 months ]The number of translated PLSs will be scored in the six months period for a participant
- Number of translated PLSs after 3 months of follow up [ Time Frame: 3 months ]The number of translated PLSs will be scored in the three months period for a participant
- Time to submitting translation [ Time Frame: 6 months ]The investigators will note the time needed to submit translation
- Satisfaction with participation in the translation project [ Time Frame: 6 months ]Likert type scale from 1 to 10 (ranging from 1-completely unsatisfactory to 10-completely satisfactory)
- Loss of participants [ Time Frame: 6 months ]Loss of participants from the trial at final follow-up of 6 months, defined as participants' message that they wish to stop translating during the trial period, without later messages during the trial that they wish to engage in translation again.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- adults ≥18 years who volunteered to translate Cochrane PLSs within the Croatian translation project.
Exclusion Criteria:
- none

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03534791
Croatia | |
University of Split School of Medicine | |
Split, Split-Dalmatia County, Croatia, 21000 |
Principal Investigator: | Dalibora Behmen, Professor | Researcher and administrator |
Responsible Party: | Dalibora Behmen, Professor, University of Split, School of Medicine |
ClinicalTrials.gov Identifier: | NCT03534791 |
Other Study ID Numbers: |
2014- 09-7672 |
First Posted: | May 23, 2018 Key Record Dates |
Last Update Posted: | July 5, 2019 |
Last Verified: | July 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Raw data will be posted to the Figshare repository (https://figshare.com/) |
Time Frame: | Within 12 months from study completion. The data will remain in the public repository indefinitely. |
Access Criteria: | Open access, publicly available |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |